Asset Details
Do you wish to reserve the book?
A perspective on the current management of advanced colorectal cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A perspective on the current management of advanced colorectal cancer
Do you wish to request the book?
A perspective on the current management of advanced colorectal cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A perspective on the current management of advanced colorectal cancer
2013
Overview
Although the median survival of patients with advanced disease has progressively increased, colorectal cancer remains a major worldwide health problem, with approximately 1 million new cases and 500,000 deaths every year. At the 2013 World Congress on Gastrointestinal Cancers, investigators have recently dealt with many clinically relevant questions, such as the preferred biologic drug to be used upfront in patients with
wild-type colorectal tumors, the optimal treatment intensity, the most suitable maintenance strategy, the need for deeper molecular information when using EGFR inhibitors and the use of antiangiogenic drugs in the elderly. Briefly summarizing all the news coming from this moving landscape, this article focuses on the results of the major randomized Phase III trials presented at the meeting.
Publisher
Future Medicine Ltd
Subject
/ Aged
/ Angiogenesis Inhibitors - adverse effects
/ Angiogenesis Inhibitors - therapeutic use
/ Antibodies, Monoclonal, Humanized - adverse effects
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Clinical Trials, Phase III as Topic
/ Colorectal Neoplasms - drug therapy
/ Colorectal Neoplasms - metabolism
/ Colorectal Neoplasms - pathology
/ elderly
/ Humans
/ NRAS
/ Proto-Oncogene Proteins - genetics
/ Proto-Oncogene Proteins p21(ras)
/ Receptor, Epidermal Growth Factor - antagonists & inhibitors
